Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ranolazine

Nature Reviews Drug Discovery volume 5, pages 453–454 (2006)Cite this article

An Erratum to this article was published on 01 July 2006

Abstract

Ranolazine (Ranexa; Cardiovascular Therapeutics) was approved by the US FDA for the treatment of chronic angina in January 2006. It is the first drug in a new class for treating this condition to be approved in the United States in more than 20 years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Abrams, J. Chronic stable angina. N. Engl. J. Med. 352, 2524–2533 (2005).

    Article  CAS  Google Scholar 

  2. Gibbons, R. J. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina), [online] (2002).

  3. Gaffney, S. M. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy 26, 135–142 (2006).

    Article  CAS  Google Scholar 

  4. Chaitman, B. R. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375–1382 (2004).

    Article  CAS  Google Scholar 

  5. Chaitman, B. R. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309–316 (2004).

    Article  CAS  Google Scholar 

  6. FDA labelling information, [online] (2006).

  7. Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904–910 (2004).

    Article  CAS  Google Scholar 

  8. Makielski, J. C. & Valdivia, C. R. Ranolazine and late cardiac sodium current — a therapeutic target for angina, arrythmia and more. Brit. J. Pharmacol. 148, 4–6 (2006).

    Article  CAS  Google Scholar 

  9. Conti, C. R. Inhibition of sodium-dependent calcium overload to treat myocardial ischemia. Clin. Cardiol. 29, 141–143 (2006).

    Article  CAS  Google Scholar 

  10. Heart Disease and Stroke Statistics—2006 Update, [online] (2006).

  11. IMS Health, MIDAS Quantum data (2005).

Download references

Author information

Authors and Affiliations

  1. Jonathan Abrams is at the Department of Internal Medicine, University of New Mexico Health Sciences Center, 1 University of New Mexico ACC 5, Albuquerque, 87131-0001, New Mexico, USA

    Jonathan Abrams

  2. Carole Jones is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Carole A. Jones

  3. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Jonathan Abrams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carole A. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abrams, J., Jones, C. & Kirkpatrick, P. Ranolazine. Nat Rev Drug Discov 5, 453–454 (2006). https://doi.org/10.1038/nrd2069

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2069

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing